Welcome to our dedicated page for Sutro Biopharma news (Ticker: STRO), a resource for investors and traders seeking the latest updates and insights on Sutro Biopharma stock.
Sutro Biopharma, Inc. (NASDAQ: STRO) is a clinical-stage biopharmaceutical company based in South San Francisco, focused on the discovery, development, and manufacturing of next-generation cancer therapeutics. The company leverages its proprietary cell-free protein synthesis platform, XpressCF®, to produce novel antibody-drug conjugates (ADCs) and bispecific antibodies that target cancer cells with precision, aiming to offer improved safety and efficacy over traditional treatments.
Key products in Sutro's pipeline include STRO-001, designed for patients with multiple myeloma and non-Hodgkin lymphoma, and STRO-002 (also known as luveltamab tazevibulin or 'luvelta') for the treatment of ovarian and endometrial cancers. The company has recently initiated Phase 2/3 clinical trials for luvelta in platinum-resistant ovarian cancer (PROC) and is progressing towards trials for endometrial cancer. Sutro is also exploring additional indications, including non-small cell lung cancer and a rare pediatric form of acute myeloid leukemia (AML).
Recent achievements include the appointment of Dr. Hans-Peter Gerber as Chief Scientific Officer and the presentation of promising preliminary data for luvelta in endometrial cancer at ESMO 2023. Financially, Sutro reported cash and investments totaling $321.1 million and an additional $34.0 million in Vaxcyte common stock as of September 30, 2023, providing a projected cash runway into the first half of 2025.
Sutro's innovative approach is not limited to its product pipeline. The company operates the world's only cGMP cell-free manufacturing facility in San Carlos, California, giving it a strategic advantage in the biopharmaceutical industry. Sutro's numerous partnerships and collaborations have generated about $785 million in payments through September 2023, reflecting the significant value of its platform.
Sutro continues to build a robust pipeline and high-value collaborations, including recent partnerships with healthcare-focused institutional investors. The company has a strong financial outlook and a growing portfolio of clinical-stage candidates aimed at transforming cancer treatment. For more information, visit Sutro Biopharma.
Sutro Biopharma (NASDAQ: STRO) announced new nonclinical data for STRO-002 and STRO-001 presented at the ASH 2021 conference, showcasing potential therapies for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Research led by Fred Hutchinson Cancer Research Center identifies FOLR1 and CD74 as actionable targets. STRO-002 exhibited strong efficacy against high-risk AML subtypes, while STRO-001 demonstrated significant cytotoxicity in both AML and ALL cells. The data supports ongoing clinical trials for both products in treating various cancer indications.
Sutro Biopharma (NASDAQ: STRO) announced CEO Bill Newell's participation in two virtual investor conferences. The Piper Sandler 33rd Annual Healthcare Conference is scheduled for November 22, 2021, at 10:00 a.m. ET, featuring a pre-recorded fireside chat. The 4th Annual Evercore ISI HealthCONx Conference will take place on November 30, 2021, at 10:05 a.m. ET, with a live fireside chat. Webcasts are accessible via Sutro's Investor Relations page, with archived replays available for 30 days.
Sutro Biopharma (NASDAQ: STRO) announced the appointment of Heidi Hunter to its Board of Directors, effective November 17, 2021. Hunter brings over 25 years of biotech leadership experience, having held significant roles at Cardinal Health, UCB, Boehringer Ingelheim, and IQVIA. CEO Bill Newell highlighted her expertise in driving the development and commercialization of new medicines. Sutro focuses on advancing innovative cancer and autoimmune therapeutics, including its leading candidates STRO-001 and STRO-002, currently in Phase 1 trials.
Sutro Biopharma (NASDAQ: STRO) reported financial results for Q3 2021, highlighting a revenue drop to $8.5 million from $17.8 million in Q3 2020. Operating expenses surged to $43.2 million, reflecting increased R&D and G&A costs. Key developments include completed enrollment for the STRO-002 Phase 1 dose-expansion cohort targeting advanced ovarian cancer and ongoing dose escalation for STRO-001 in B-cell malignancies. Sutro has a cash runway into H2 2023, with substantial cash reserves of $254.2 million as of September 30, 2021.
Sutro Biopharma (NASDAQ: STRO), a clinical-stage drug development company, announced CEO Bill Newell will present at three virtual investor conferences in November 2021. The presentations include:
- Credit Suisse 30th Annual Healthcare Conference: Nov. 10, 2021, 4:20 p.m. EST
- Stifel Virtual Healthcare Conference: Nov. 15, 2021, 1:20 p.m. EST
- Jefferies London Healthcare Conference: Nov. 18, 2021, 3:00 a.m. EST
Live webcasts can be accessed via the company's website.
Sutro Biopharma and BioNova Pharmaceuticals have announced an option agreement for the development and commercialization of STRO-001, a CD74-targeting ADC, in Greater China. BioNova will pay Sutro an initial $4 million and potential milestone payments totaling up to $200 million. Sutro maintains global rights outside Greater China. The collaboration aims to address unmet medical needs in hematologic cancers, with BioNova committed to advancing STRO-001 through clinical development and regulatory approval. Sutro will receive tiered royalties based on sales in the region.
Sutro Biopharma (NASDAQ: STRO) announced on Sept 30, 2021, an extension of its research term for the cytokine derivative program with Merck for an additional two years, aimed at completing preclinical research for a second candidate. Sutro is eligible for up to $10 million from this extension. The collaboration leverages Sutro's proprietary protein engineering platforms, XpressCF® and XpressCF+™, and has previously resulted in milestone payments of $5 million and $15 million for earlier collaborations. The ongoing research could lead to innovative cancer treatments.
Sutro Biopharma announced on September 15, 2021, that its Compensation Committee granted restricted stock units (RSUs) of 150,000 shares and stock options for 145,000 shares to three new employees. These grants were part of an inducement to join Sutro and comply with Nasdaq rules. The RSUs will vest annually over four years, while stock options will vest annually and monthly thereafter, also over four years. Sutro specializes in developing next-generation cancer therapeutics through its protein engineering platforms, advancing multiple ADC candidates in clinical trials.
Sutro Biopharma (NASDAQ: STRO) announced the addition of two key executives, Nicole M. Chieffo and Werner Rubas, to its leadership team. Chieffo, with over 25 years in clinical operations, previously held senior roles at Janssen Pharmaceuticals, leading to successful drug approvals. Rubas brings 30 years of experience, most recently as Executive Director at Nektar Therapeutics. Chief Medical Officer Arturo Molina and President of Research Trevor Hallam highlighted the expertise these leaders bring to advance Sutro's pipeline. The company focuses on developing cancer therapeutics, including its ADCs STRO-001 and STRO-002.
Sutro Biopharma (NASDAQ: STRO) announced that CEO Bill Newell will participate in the 2021 Wells Fargo Securities Healthcare Conference via a virtual fireside chat on September 9 at 3:20 p.m. ET. A live webcast will be available on Sutro's website, with archived replays accessible for 30 days post-event.
Sutro specializes in precise protein engineering to develop innovative cancer therapeutics, with candidates like STRO-001 and STRO-002 in clinical trials.
FAQ
What is the current stock price of Sutro Biopharma (STRO)?
What is the market cap of Sutro Biopharma (STRO)?
What is Sutro Biopharma's focus?
What are Sutro Biopharma's key products?
What recent achievements has Sutro Biopharma accomplished?
What is Sutro Biopharma's financial outlook?
Where is Sutro Biopharma headquartered?
What is unique about Sutro Biopharma's manufacturing capabilities?
What collaborations has Sutro Biopharma recently entered into?
What are the upcoming milestones for Sutro Biopharma?
How can I learn more about Sutro Biopharma?
Who should I contact for more information about Sutro Biopharma?
